|
A∙WOLcome The A∙WOL Consortium consists of both academic and industrial partners funded by The Bill & Melinda Gates Foundation, whose aim is to develop a new chemotherapy treatment against Wolbachia - a bacterial endosymbiont of filarial nematodes responsible for onchocerciasis (river blindness) and lymphatic filariasis (elephantiasis). This will be achieved through the development of technologies and tools to identify and evaluate novel drugs and targets, and to develop and refine existing drugs and regimes. The aim is to create products compatible with mass drug administration (MDA) programmes for human filariasis and/or provide an alternative treatment in the event of drug-resistance to current treatments. The A∙WOL website has been created to provide information on our programme, to increase the awareness of lymphatic filariasis and onchocerciasis and to highlight the urgent need for new treatments.
A∙WOL Dispatches
September 8th 2008 New drug for parasitic diseases developed June 14th 2007 River blindness resistance fears April 18th 2007 March 27th 2007 Gates gives third disease grant September 24th 2006 Pill 'defeats elephant disease’ June 5th 2005 Disfiguring disease halted by pill March 7th 2002 Bacteria ‘holds key’ to river blindness
Contact Us The A∙WOL Consortium |
|
Last Updated: 12th October 2010